Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease (ESRD) and is therefore a major burden on the healthcare system. Patients with DKD are highly susceptible to developing cardiovascular disease, which contributes to increased morbidity and mortality rates. While progress has been made to inhibit the acceleration of DKD, current standards of care reduce but do not eliminate the risk of DKD. There is growing appreciation for the role of inflammation in modulating the process of DKD. The focus of this review is on providing an overview of the current status of knowledge regarding the pathologic roles of inflammation in the development of DKD. Finally, we summarize recent therapeutic advances to prevent DKD, with a focus on the anti-inflammatory effects of newly developed agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“Importantly, this trial showed no imbalance in rates of amputation or bone fracture, and no new safety concerns were identified [53].”
BackgroundEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 1×
“For example, the renal composite outcomes (doubling of creatinine, renal replacement therapy, or renal death) decreased by 46% in patients with type 2 diabetes treated with empagliflozin [52].”
BackgroundNrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878 · cited 1×
“reported that Nrf2 binds to the regulatory regions of inflammatory genes and thereby induces their transcription in macrophages and alleviates RNA polymerase II recruitment [37].”
BackgroundAdler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Transcriptome Analysis of Human Diabetic Kidney Disease
Woroniecka, K. I., Park, A. S. D., Mohtat, D., Thomas, D. B., Pullman, J. M., & Susztak, K. (2011) · Diabetes · doi:10.2337/db10-1181 · Cited by 642
Pathogenesis and Treatment of Chronic Kidney Disease: A Review of Our Recent Basic and Clinical Data
Tomino, Y. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000368458 · Cited by 566
Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D., & Zhang, D. D. (2011) · Diabetes · doi:10.2337/db11-0807 · Cited by 507
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 493
Cited by
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy
Yang, J., & Liu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816400 · Cited by 281
Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives
Tanase, D. M., Gosav, E. M., Anton, M. I., Floria, M., Seritean Isac, P. N., Hurjui, L. L., Tarniceriu, C. C., Costea, C. F., Ciocoiu, M., & Rezus, C. (2022) · Biomolecules · doi:10.3390/biom12091227 · Cited by 198
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
Metadata
- Authors
- Matoba, K., Takeda, Y., Nagai, Y., Kawanami, D., Utsunomiya, K., & Nishimura, R.
- Affiliations
- Jikei University School of Medicine (JP)
- Fukuoka University (JP)
- Corresponding author
- Matoba, Keiichiro
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-07-10
- Volume
- 20
- Issue
- 14
- Pages
- 3393
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6678414
- OpenAlex
- W2958949191
- Semantic Scholar
- 1919f7691771fef371eec317a2f8802ae08a78f7
- Cited by
- 223
- References
- 84
- Citations by year
- 2026: 19 · 2025: 30 · 2024: 40 · 2023: 26 · 2022: 44 · 2021: 36 · 2020: 22 · 2019: 5
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science (18K15985)
- Ichiro Kanehara Foundation (N/A)
- MSD Life Science Foundation (N/A)
- Yokoyama Foundation for Clinical Pharmacology (N/A)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- diabetic nephropathy, inflammation, pathogenesis, end-stage renal disease, cardiovascular disease, anti-inflammatory therapy, novel therapeutic agents
- MeSH terms
- Animals, Diabetic Nephropathies, Disease Susceptibility, Humans, Inflammation, Signal Transduction, Biomarkers, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease. https://app.cochat.ai/papers/10.3390/ijms20143393
- The paper
- Matoba, K., Takeda, Y., Nagai, Y., Kawanami, D., Utsunomiya, K., & Nishimura, R. (2019). Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20143393
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.